Long term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection
- PMID: 8553295
- PMCID: PMC1021345
- DOI: 10.1136/thx.50.12.1246
Long term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection
Abstract
Background: Diffuse panbronchiolitis is a chronic infection of the lower respiratory tract common among the Japanese people, with a persistent Pseudomonas aeruginosa infection in the late stage and sustained neutrophil retention in the airways. The long term effect of erythromycin was examined retrospectively in a group of patients with diffuse panbronchiolitis, with and without P aeruginosa infection, and the relationship between drug-induced bacterial clearance and clinical improvement was investigated.
Methods: The history, daily volume of sputum, type of organisms in sputum cultures, pulmonary function tests, arterial blood gas tensions, and chest radiographs were compared in 16 patients with diffuse panbronchiolitis with P aeruginosa infection and 12 without. The total and differential cell counts in the bronchoalveolar lavage (BAL) fluid were compared in 14 of the 28 patients (five of whom were infected with P aeruginosa) before and after 1-12 months of treatment with erythromycin (600 mg/day). The outcome of treatment in patients showing clearance of organisms on repeated sputum cultures was compared with that in those demonstrating persistence of bacteria in the sputum and patients with normal flora.
Results: Erythromycin improved respiratory function and arterial blood gas tensions irrespective of the presence or absence of P aeruginosa in the sputum. Treatment also resulted in a reduction in the BAL fluid total cell count and the percentage of neutrophils in both groups of patients. There were no differences between patients in whom the bacteria cleared and those with persistent bacteria or patients with a normal flora with regard to the degree of improvement of respiratory function, arterial blood gas tensions, and BAL fluid cell composition.
Conclusion: The results suggest that the efficacy of erythromycin in diffuse pan-bronchiolitis may be due to anti-inflammatory effect, independent of P aeruginosa infection or bacterial clearance.
Similar articles
-
New approaches to Pseudomonas aeruginosa lower respiratory tract infections.Verh K Acad Geneeskd Belg. 1995;57(2):109-22. Verh K Acad Geneeskd Belg. 1995. PMID: 7571853
-
Characterization of Pseudomonas aeruginosa from subjects with diffuse panbronchiolitis.Microbiol Spectr. 2024 Nov 5;12(11):e0053024. doi: 10.1128/spectrum.00530-24. Epub 2024 Oct 8. Microbiol Spectr. 2024. PMID: 39377602 Free PMC article.
-
Diffuse panbronchiolitis--pathophysiology and treatment mechanisms.Int J Antimicrob Agents. 2001;18 Suppl 1:S83-7. doi: 10.1016/s0924-8579(01)00403-4. Int J Antimicrob Agents. 2001. PMID: 11574201 Review.
-
The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial.Lancet Respir Med. 2014 Dec;2(12):988-96. doi: 10.1016/S2213-2600(14)70213-9. Epub 2014 Oct 14. Lancet Respir Med. 2014. PMID: 25458200 Clinical Trial.
-
A review of the recent progress in treatment of patients with diffuse panbronchiolitis associated with Pseudomonas aeruginosa infection in Japan.Antibiot Chemother (1971). 1991;44:94-8. doi: 10.1159/000420303. Antibiot Chemother (1971). 1991. PMID: 1801651 Review. No abstract available.
Cited by
-
Antibacterial and immunomodulatory properties of azithromycin treatment implications for periodontitis.Inflammopharmacology. 2013 Aug;21(4):321-38. doi: 10.1007/s10787-012-0165-1. Epub 2013 Feb 28. Inflammopharmacology. 2013. PMID: 23446952 Review.
-
New and emerging therapies for pulmonary complications of cystic fibrosis.Drugs. 2001;61(10):1379-85. doi: 10.2165/00003495-200161100-00001. Drugs. 2001. PMID: 11558827 Review.
-
Mechanisms of action and clinical application of macrolides as immunomodulatory medications.Clin Microbiol Rev. 2010 Jul;23(3):590-615. doi: 10.1128/CMR.00078-09. Clin Microbiol Rev. 2010. PMID: 20610825 Free PMC article. Review.
-
Inhibitory effect of erythromycin on superoxide anion production by human neutrophils primed with granulocyte-colony stimulating factor.Antimicrob Agents Chemother. 1998 Jul;42(7):1866-7. doi: 10.1128/AAC.42.7.1866. Antimicrob Agents Chemother. 1998. PMID: 9661038 Free PMC article. No abstract available.
-
Pulmonary Hypertension Associated with Diffuse Panbronchiolitis That Improved with Erythromycin and Home Oxygen Therapy.Intern Med. 2023 Aug 1;62(15):2231-2236. doi: 10.2169/internalmedicine.0929-22. Epub 2022 Dec 14. Intern Med. 2023. PMID: 36517032 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical